Hormonal
GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) produce clinically significant weight loss (8-24%) in obese patients, serving as an effective alternative to bariatric surgery for preoperative optimization in joint arthroplasty candidates.
GLP-1 agonists like Semaglutide (Wegovy/Ozempic) and Tirzepatide (Zepbound/Mounjaro) are highly effective for weight loss, achieving 15-20% body weight reduction in clinical trials. For patients with osteoarthritis, this weight loss can significantly reduce joint pain and improve surgical outcomes. If you are considering joint replacement, discuss these medications with your doctor as a potential bridge to surgery. Be aware that gastrointestinal side effects like nausea are common initially but often subside as your body adjusts to the medication. Oral versions are also available if you prefer to avoid injections.
The recent phase 3 weight-loss data from semaglutide, liraglutide, and tirzepatide has changed the medically supervised weight-loss landscape given the safety and efficacy of this class of medications... Semaglutide and liraglutide are glucagon-like peptide-1 (GLP-1) receptor agonists, and tirzepatide is both a GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor dual agonist, now being used extensively for medically supervised weight loss.
Why this rating
The paper cites multiple large-scale Phase 3 randomized controlled trials (SCALE, STEP, SURMOUNT) with thousands of participants, though it is a review paper summarizing these rather than a primary trial itself.
Source
Glucagon-Like Peptide Receptor-1 Agonists Used for Medically-Supervised Weight Loss in Patients With Hip and Knee Osteoarthritis: Critical Considerations for the Arthroplasty Surgeon
Nathanael D. Heckmann et al. · Arthroplasty Today · 2024
DOI 10.1016/j.artd.2024.101327
More from this paper
- GLP-1 receptor agonists delay gastric emptying, increasing the risk of pulmonary aspiration during anesthesia, necessitating specific perioperative holding periods or gastric assessment before elective surgery.Good
- GLP-1 receptor agonists may provide direct anti-inflammatory and disease-modifying benefits to osteoarthritic joints, independent of weight loss, by reducing pro-inflammatory cytokines and protecting chondrocytes.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →